The HCPFive: Top News for Healthcare Providers from the Week of 08/02

Welcome to The HCPFive, your go-to roundup for the latest healthcare news and breakthroughs, curated specifically for busy healthcare professionals.Each week, we highlight 5 key developments or headlines from healthcare that you need to know — whether it's a cutting-edge treatment, regulatory updates, or innovations shaping the future of medicine.

This week's top stories include new 2-year results from the phase 3 VISIONARY trial of sibeprenlimab-szsi (Voyxact) in IgA nephropathy (IgAN), the US Food and Drug Administration (FDA) Fast Track Designation of Aravax's investigational peptide immunotherapy PVX108 for peanut allergy, and the FDA approvals of Mucinex 12HR Cold & Fever Multi-Symptom for fever, cough, chest congestion and body pain in cold/flu, oveporexton (Orzeyful) tablets for narcolepsy type 1 in adults, and mRNA-1010 (mFLUSIVA) as a seasonal influenza vaccine for use in all adults ≥ 50 years of age.

With The HCPFive, you'll get the essential takeaways to stay informed and ahead of the curve. Here's your quick dive into the top stories for the week of August 2, 2026 — let's jump in!

Sibeprenlimab (Voyxact) Stabilizes Kidney Function in IgAN

On August 3, 2026, 2-year results from the phase 3 VISIONARY trial were presented in a late-breaking session at GlomCon Hawaii 2026, with data showing sibeprenlimab-szsi (Voyxact) returned the annualized rate of kidney function decline in IgAN to a near-physiologic level.

The trial met its key secondary endpoint, the annualized estimated glomerular filtration rate (eGFR) slope was +0.3 mL/min/1.73 m²/year (95% Confidence Interval [CI], -0.4 to 0.9) with sibeprenlimab, compared with -4.2 mL/min/1.73 m²/year (95% CI, -4.9 to -3.6) with placebo, a treatment difference of +4.5 mL/min/1.73 m²/year (95% CI, 3.6 to 5.4; P <.0001).

Aravax's PVX108 Receives FDA Fast Track Designation for Peanut Allergy

On August 3, 2026, The FDA granted Fast Track designation to PVX108, Aravax's investigational peptide immunotherapy for peanut allergy. PVX108 enters this pathway as a peptide-based immunotherapy distinct from oral immunotherapy products such as Palforzia, which was officially discontinued as of July 31, 2026. PVX108 is designed to retrain immune tolerance without the acute allergic reactions associated with existing desensitization approaches.

FDA Approves Mucinex 12HR Cold & Fever Multi-Symptom for OTC Use

On August 5, 2026, Reckitt announced the FDA approval of Mucinex 12HR Cold & Fever Multi-Symptom, making it the first and only FDA-approved OTC cold and flu medication that treats fever, cough, chest congestion and body pain for 12 hours. The fixed-dose product contains guaifenesin, dextromethorphan hydrobromide, and naproxen sodium in a bilayer tablet.

FDA Approves Oveporexton (Orzeyful) for Narcolepsy Type 1

On August 5, 2026, the FDA approved oveporexton (Orzeyful) tablets for narcolepsy type 1 in adults, the first medicine to directly target orexin signaling loss and address the disorder as a complete condition.

Oveporexton is the first agent to activate the OX2R receptor directly, restoring the signal lost when orexin-producing neurons are destroyed. The approval was granted to Takeda Pharmaceuticals America, Inc, following Breakthrough Therapy Designation and Priority Review.

mFLUSIVA Receives FDA Approval for Influenza in Adults 50 and Older

On August 6, 2026, the FDA approved mRNA-1010 (mFLUSIVA), Moderna's mRNA-based seasonal influenza vaccine, for use in all adults ≥ 50 years of age, granting full approval in adults aged 50 to 64 years and accelerated approval in adults aged ≥ 65 years. The decision marks the first mRNA-based influenza vaccine cleared in the United States and follows a unanimous recommendation from the FDA's Vaccines and Related Biological Products Advisory Committee.